chevron_leftBack
As of 24 April 2025, Delcath Systems, Inc. has a market cap of $399.17M USD, ranking #13231 globally and #2433 in the United States. It ranks #1300 in the Healthcare sector, and #143 in the Medical Devices industry.
Key Stats
Market Cap
$399.17MUSD
Enterprise Value
$347.31MUSD
Revenue (TTM)
$37.21MUSD
EBITDA (TTM)
-$12.28MUSD
Net Income (TTM)
-$26.39MUSD
EBITDA Margin
-33%
Profit Margin
-71%
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Medical Devices
CEO
Gerard Michel
open_in_new
Employees
96
Founded
1988
Website
delcath.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 0.7% | 3.5% | -13% | -21% | 5.1% | 117% |
Upcoming Earnings
Earnings Date
Tue, May 13
Earnings Time
sunny
Before Open
EPS Estimate
$0.0300
Revenue Estimate
$16.83M
436% yoy
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
DCTH
Delcath Systems Inc
ISIN: US24661P8077
Shares Out.:
Shares Outstanding:
33.433M1
Shares Float:
28.004M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
11.95 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Delcath Systems, Inc.
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. The company was founded in 1987 and is headquartered in New York, New York.
